CMPXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Compass Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$0.83−0.03 (-2.91%)
Close on Oct 19, 2026
- Market cap
- $155.98M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -115.2% | -41.3% | |
| Return on assets | – | -71.7% | -36.9% | |
| Current ratio | 0.07 | 4.97 | 15.02 | |
| Debt to equity | – | 0.23 | – | |
| Net debt to EBITDA | – | 1.49× | – | |
| Interest coverage | – | -30.6× | – | |
| Diluted shares | – | 31M | 158M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Compass Therapeutics generated $188.41M from operations and spent $1.88M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$188.41M
Used
$1.88M
Capital expenditure$1.88M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-5808.8%
×Asset turnover0.01×
×Equity multiplier1.09×
=Return on equity, FY2024-36.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2024 | -5808.8% | 0.01× | 1.09× | -36.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$66.49M
- Cash generatingOperating cash flow above zero-$49.14M
- Return on assets improvedROA up on the prior year-31.5% → -47.4%
- Earnings backed by cashOperating cash flow above net income-$49.14M vs -$66.49M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose14.96 → 15.02
- No dilutionShare count did not rise137M → 158M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.01 → 0.00